

Board of Directors

12th May 2022

Paper title:	Finance Update 2021/22	Agenda item
Presented by:	Mike Woodhead, Director of Finance, Contracting and Estates	
Prepared by:	Claire Risdon, Deputy Director of Finance	21

Purpose of the report			
The purpose of the report is to provide the Trust Board with:	For approval		
 an overview on the financial performance for M12, for both 	For discussion	X	
the Trust and the ICS	For information		

Executive summary

Trust Financial Performance 2021/22 (Paper 21.1)

Trust performance for the period April 2021 to March 2022 is a surplus of £1.365m compared to a planned breakeven position. This includes the receipt of national funding to support COVID costs for the vaccination centre in Bradford and PPE supplied nationally of £3.21m.

Capital funding has been secured through the year amounting to £7.775m (£6.03m ICS CDEL and £1.745m in year PDC approved). Total Trust capital expenditure for the year is £6.011m, resulting in a planned underspend of £1.764m which has been used to support wider ICS capital priorities

ICS Financial Performance 2021/22 (Paper 21.2)

The headline position for the ICS for month 12:

- Favourable position at Month 12 of £29.8m surplus
- ICS capital forecast to be over committed by allowable £7.1m funded from inter-ICS transfer, and national cover expected for Airedale's Reinforced Autoclaved Aerated Concrete (RAAC) replacement programme. This overspend has been agreed by NHSEI.

Do the recommendations in this paper have any impact upon the requirements of the	State below 'Yes' or 'No'	If yes please set out what action has been taken to address this in your paper
protected groups identified by the Equality Act?	No	

Recommendation

The Board of Directors is asked to:

- Note the outturn financial position of the Trust and the ICS; and
- Highlight further assurances required.



Strategic vision				
Please mark those that apply with an X				
Providing excellent quality services and seamless access	Creating the best place to work	Supporting people to live to their fullest potential	Financial sustainability growth and innovation	Governance and well-led
Х	Х	X	X	X

Care Quality Commission domains				
Please mark those that apply with an X				
Safe	Effective	Responsive	Caring	Well Led
Х	Х	Х	Х	X

Relationship	The work contained with this report links to the strategic risk(s) as identified in
to the Board	the BAF:
Assurance Framework (BAF)	 SO6: To make effective use of our resources to ensure that services are clinically, environmentally, and financially sustainable SO5: To value partnership ensuring that we collaborate to deliver
	 maximum impact on health inequalities SO2: To prioritise our people, ensuring they have the right skills, suitable workspaces and feel valued and motivated
Links to the Strategic Organisational Risk Register	The work contained with this report links to the following corporate risks as identified in the SORR: Risk 2536: If we do not make effective use of our resources this may result in regulatory interventions, as well as impacts on quality of
(SORR)	services.
Compliance and regulatory implications	The following compliance and regulatory implications have been identified as a result of the work outlined in this report: • The NHS Single Oversight Framework requires providers to report performance against national requirements including quality of care, financial performance and sustainability, and delivery of national standards (though some reporting is suspended during the Covid-19 pandemic)